Nodus Oncology launches with funding from Cumulus

Nodus Oncology, a novel biotech company focused on developing first and best-in-class molecules inhibiting novel DNA damage response (DDR) targets, has launched with seed funding from Cumulus Oncology and announced a partnership with the Lead Discovery Center (LDC).

The Scottish company is being led by chief executive Ian Waddell, who also serves chief scientific officer at Cumulus. Dr Waddell has more than 30 years’ experience in leading successful R&D programs as well as extensive and in-depth oncology expertise, including in the DDR field.

He said: "I am excited to launch Nodus Oncology today and to be leading the company as its chief executive as we look to grow the company and its pipeline. Nodus is focused on developing the next wave of cancer therapeutics in the DDR space and I am looking forward to working with colleagues at LDC to pursue the development of differentiated programs against new targets in the DDR area."